Ann: Neuren receives DAYBUE sales milestone payment of US$50m, page-9

They still have $40m~ of the existing buyback allocated, but I suppose it could happen. There was the initial positive suprise of the PRV sale value and then there's a further suprise of the FX impact. Whilst the PMS Phase 3 FDA endpoint isn't agreed to yet, the shorter trial is also another positive for surplus cash because the costs per Phase 3 will likely be in the mid to lower range that Jon previously suggested. The interest they get pays all other operating expenses, so we've literally only got to think about the P3 costs which is an incredible place to be as shareholders.